Section of Hematology, Yale University, New Haven, CT 06510, USA.
Curr Opin Immunol. 2010 Apr;22(2):245-50. doi: 10.1016/j.coi.2010.01.011. Epub 2010 Feb 9.
A growing body of data points to not only intraclonal heterogeneity and hierarchy of growth potential, but also plasticity of cellular differentiation within human tumors. Recent studies have also identified surprising overlap between pathways that regulate pluripotency in embryonal stem (ES) cells and oncogenesis. While there is a long history of targeting embryonal tissues toward cancer vaccines, recent identification of crucial stemness pathways in ES cells as well as putative cancer stem cells (CSCs) provides novel opportunities for antigen-specific targeted therapy. Here we discuss recent insights into the capacity of the immune system to target these pathways. Immunologic targeting of pathways associated with stemness has implications for both immune regulation of tumor growth as well as regenerative therapies with embryonal stem cells.
越来越多的证据不仅表明了克隆内异质性和生长潜力的等级，而且还表明了人类肿瘤中细胞分化的可塑性。最近的研究还发现，调节胚胎干细胞 (ES) 细胞多能性和肿瘤发生的途径之间存在惊人的重叠。虽然针对胚胎组织的癌症疫苗已有很长的历史，但最近在 ES 细胞和潜在的癌症干细胞 (CSC) 中确定关键的干性途径为抗原特异性靶向治疗提供了新的机会。在这里，我们讨论了免疫系统靶向这些途径的最新见解。免疫靶向与干性相关的途径不仅对肿瘤生长的免疫调节具有重要意义，而且对胚胎干细胞的再生治疗也具有重要意义。
